TRAVASE
LOE ApproachingNDATOPICALOINTMENTPriority Review
Approved
Jun 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVASE is a topical ointment small molecule approved in 1969 for debridement of necrotic tissue and eschar in wound care. The mechanism of action involves enzymatic activity to promote tissue breakdown and wound healing. This is a legacy product with a well-established but aging indication profile.
LOE Approaching
Declining product with low current linked job openings; team size likely lean and focused on maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRAVASE represents a career in legacy product stewardship rather than growth opportunity; roles focus on maintaining market share and operational efficiency in a declining category. This is suitable for professionals seeking stability over expansion, or as a stepping stone into portfolio rationalization and divestiture strategy.
Brand ManagerField Sales Representative
Worked on TRAVASE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.